Background Neonatal hyperbilirubinemia risk factors determination is challenging due to the lack of quantifiable indicators for bilirubin production, resulting in phototherapy decisions made without real-time information. End-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc) may be helpful for identifying hemolysis, but evidence on the application of ETCOc as a risk factor for the development of neonatal hyperbilirubinemia is scarce. This study aimed to evaluate whether the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories and thus phototherapy thresholds can reduce the rate of phototherapy within the first seven days of life. Methods This is a randomized clinical trial including near-term and term infants with a transcutaneous bilirubin <InlineEquation ID="IEq1"> <InlineMediaObject> <ImageObject Color="BlackWhite" FileRef="12519_2025_954_Article_IEq1.gif" Format="GIF" Height="11" Rendition="HTML" Resolution="72" Type="Linedraw" Width="17" /> </InlineMediaObject> <EquationSource Format="TEX">$>$</EquationSource> <EquationSource Format="MATHML"><math> <mo>></mo> </math></EquationSource> </InlineEquation> 40th percentile within 72 hours after birth in a single center in Guangdong, China. Newborns were randomized to receive ETCOc-adjusted risk assessment or empirical assessment per local practice to establish phototherapy thresholds. The primary outcome was the rate of phototherapy within seven days of life. Secondary outcomes were postnatal hours at phototherapy, total serum bilirubin and ETCOc before phototherapy, severe hyperbilirubinemia and phototherapy duration. Results A total of 2500 infants were enrolled and randomized. Phototherapy within seven days of life occurred in 237 infants (18.9%) in the intervention group and 281 infants (22.5%) in the control group [adjusted relative risk: 0.85; 95% confidence interval (CI): 0.73, 0.98]. The ETCOc before phototherapy was 0.28 parts per million higher (95% CI: 0.10, 0.46) in the intervention group. The rate of subsequent severe hyperbilirubinemia was not significantly different, and other secondary outcomes were comparable between the two groups. Conclusions For near-term and term infants at risk of neonatal hyperbilirubinemia, the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories can decrease the rate of phototherapy at seven days of life. Integrating the ETCOc to adjust the phototherapy threshold is helpful in the management of severe hyperbilirubinemia. Graphical Abstract

End-tidal CO corrected for ambient CO risk adjusted phototherapy threshold for the management of neonatal hyperbilirubinemia: a randomized clinical trial

期刊论文
出版模式：

开放获取
发表日期：

2025年8月4日

查看全文

Ge Yang,
Li Deng,
Kun Zhang,
Hui-Juan Liu,
Xin-Rui Fu,
Yue Hu,
Xiao-Dan Yan,
Xiao-Yun Zhou,
Wei Luo,
Si-Yao Wang,
Xiao-Tong Ye,
Tian-Lang Zhang,
Fan Li,
Zhuan-Xia Huo,
Yan Jiang,
Shan Zeng,
De-Hua Wu,
Yuan Yuan,
Hua-Yan Zhang

摘要

Background

Neonatal hyperbilirubinemia risk factors determination is challenging due to the lack of quantifiable indicators for bilirubin production, resulting in phototherapy decisions made without real-time information. End-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc) may be helpful for identifying hemolysis, but evidence on the application of ETCOc as a risk factor for the development of neonatal hyperbilirubinemia is scarce. This study aimed to evaluate whether the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories and thus phototherapy thresholds can reduce the rate of phototherapy within the first seven days of life.

Methods

This is a randomized clinical trial including near-term and term infants with a transcutaneous bilirubin $>$ $>$ 40th percentile within 72 hours after birth in a single center in Guangdong, China. Newborns were randomized to receive ETCOc-adjusted risk assessment or empirical assessment per local practice to establish phototherapy thresholds. The primary outcome was the rate of phototherapy within seven days of life. Secondary outcomes were postnatal hours at phototherapy, total serum bilirubin and ETCOc before phototherapy, severe hyperbilirubinemia and phototherapy duration.

Results

A total of 2500 infants were enrolled and randomized. Phototherapy within seven days of life occurred in 237 infants (18.9%) in the intervention group and 281 infants (22.5%) in the control group [adjusted relative risk: 0.85; 95% confidence interval (CI): 0.73, 0.98]. The ETCOc before phototherapy was 0.28 parts per million higher (95% CI: 0.10, 0.46) in the intervention group. The rate of subsequent severe hyperbilirubinemia was not significantly different, and other secondary outcomes were comparable between the two groups.

Conclusions

For near-term and term infants at risk of neonatal hyperbilirubinemia, the use of ETCOc to adjust neonatal hyperbilirubinemia risk categories can decrease the rate of phototherapy at seven days of life. Integrating the ETCOc to adjust the phototherapy threshold is helpful in the management of severe hyperbilirubinemia.

Graphical Abstract